Research ArticleBasic Science Investigations
Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
Vladimir Tolmachev, Thuy A. Tran, Daniel Rosik, Anna Sjöberg, Lars Abrahmsén and Anna Orlova
Journal of Nuclear Medicine June 2012, 53 (6) 953-960; DOI: https://doi.org/10.2967/jnumed.111.101527
Vladimir Tolmachev
Thuy A. Tran
Daniel Rosik
Anna Sjöberg
Lars Abrahmsén

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 6
June 1, 2012
Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
Vladimir Tolmachev, Thuy A. Tran, Daniel Rosik, Anna Sjöberg, Lars Abrahmsén, Anna Orlova
Journal of Nuclear Medicine Jun 2012, 53 (6) 953-960; DOI: 10.2967/jnumed.111.101527
Jump to section
Related Articles
Cited By...
- Engineering of Affibody Molecules
- Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients
- ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- Imaging of Platelet-Derived Growth Factor Receptor {beta} Expression in Glioblastoma Xenografts Using Affibody Molecule 111In-DOTA-Z09591
- Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein